GLP-1 FFM Systematic Review ACP 2026
Core PMIDs: PMID 39481534 (Annals ACP 2026) | PMID 41772149 (Nat Med 2026) | PMID 40544433 (NEJM 2025) Evidence grades: Confirmed > Supported > Reported > Contested > Gap Parent hub: GLP-1 Muscle Preservation
TL;DR
A landmark Annals of Internal Medicine systematic review (ACP 2026, PMID 39481534) found that 34.9% median of GLP-1 weight loss is fat-free mass (IQR 19–48.2%), with 68% of 36 RCTs exceeding the ~25% caloric restriction benchmark. The only clinically proven pharmacologic muscle preservation strategy is bimagrumab + semaglutide (Phase 2 RCT, PMID 41772149). CagriSema is approaching regulatory approval with plausible FFM benefit (PMID 40544433). The critical caveat: zero of 36 RCTs measured physical function (grip strength, SPPB, falls) as a primary endpoint — the clinical significance of FFM loss is unknown.
The 34.9% Figure — ACP 2026 Systematic Review
Evidence grade: Supported Source: Annals of Internal Medicine, ACP 2026 presentation; PMID 39481534
| Metric | Value |
|---|---|
| Median FFM proportion of weight lost | 34.9% |
| Interquartile range | 19–48.2% |
| RCTs exceeding ~25% diet benchmark | 68% (25 of 36) |
| Median RCT sample size | n=71 per study |
Context: In a 15 kg weight loss on semaglutide, 34.9% FFM ≈ ~5.2 kg of lean mass lost. This is comparable to bariatric surgery proportions (25–30% FFM).
Important caveats:
- The 25% comparator benchmark may not be appropriate for rapid pharmaceutical weight loss
- DXA/BIA during rapid weight change measures glycogen depletion and fluid shifts as FFM loss — may overstate true skeletal muscle protein loss
- IQR of 19–48.2% indicates enormous spread; median is not representative of any specific agent
- No RCT has demonstrated functional impairment, falls, or fractures attributable to FFM loss
Cross-trial comparison of FFM% across GLP-1 agents — all indirect, no head-to-head DXA RCT exists:
| Agent | FFM% Estimate | Evidence Grade | Notes |
|---|---|---|---|
| Semaglutide 2.4 mg | ~25–35% | Supported | DXA substudy STEP 1 |
| Tirzepatide 15 mg | ~33–39% | Reported (post-hoc) | SURPASS program; no primary DXA endpoint |
| Retatrutide | ~33–38% | Reported | Phase 2; glucagon component theoretically catabolic |
| Bimagrumab + semaglutide | Lean preserved/increased | Confirmed (Phase 2 RCT) | Only proven pharmacologic strategy |
| CagriSema | Numerically better than semaglutide | Supported (Phase 3) | DXA not primary endpoint; FDA decision 2026–2027 |
| MariTide | Unknown | Gap | GIP antagonism — could worsen muscle partitioning |
| Orforglipron | Unknown | Gap | No DXA body composition data |
| Survodutide | Unknown | Gap | GLP-2 component theoretically gut-protective |
⚠️ No head-to-head DXA body composition RCT exists for any pair of GLP-1 agents. All comparative claims are hypothesis-generating only.
Bimagrumab + Semaglutide: The Only Proven Strategy
Evidence grade: Confirmed Source: Nat Med 2026; PMID 41772149; BELIEVE Phase 2 RCT (n=507), 48 weeks
The BELIEVE trial tested bimagrumab (ActRII/myostatin blockade) + semaglutide 2.4 mg across 9 arms.
| Arm | Total Weight Change | Lean Mass Change | Lean % of Weight Lost |
|---|---|---|---|
| Semaglutide 2.4 mg alone | −14.2 kg | Lost (−3.9 kg) | 28.9% |
| Bimagrumab 30 mg/kg alone | −9.3 kg | Gained (+0.4 kg) | >100% (anabolic) |
| Bimagrumab + semaglutide 2.4 mg | −17.8 kg | Preserved/increased | 7.3% |
Key findings:
- 67% reduction in proportional lean mass loss vs. semaglutide alone
- Bimagrumab monotherapy was the only obesity pharmacotherapy with net anabolic lean mass signal in humans
- Combo arm achieved the most total weight loss (−17.8 kg) with the least lean loss (7.3% of total)
- No clinically significant BMD changes at 48 weeks
Critical limitation: BELIEVE did not measure physical function (grip strength, 6-minute walk). The sIBM bimagrumab extension data (PMID 32690797) showed +4.5% thigh muscle volume but progressive functional decline — pharmacological lean mass gain does not automatically translate to strength or mobility improvement.
Status: Investigational only. Bimagrumab approved for Barth syndrome (Sep 2025) — NOT for obesity/GLP-1 combo. Phase 3 required. No regulatory timeline announced.
See Bimagrumab Semaglutide Combo Obesity for full detail.
CagriSema: Approaching Approval, Plausible FFM Benefit
Evidence grade: Supported Source: REDEFINE-1 Phase 3 RCT; NEJM 2025; PMID 40544433; n=3,417
- −20.4% total body weight loss at 68 weeks (superior to semaglutide monotherapy)
- Body composition substudies show numerically better FFM preservation vs. semaglutide alone
- DXA was not the primary endpoint — exact FFM% is not definitively quantified
- FDA decision expected 2026–2027
Mechanistic rationale (Supported, not proven): Amylin receptor agonism in the hypothalamus may exert anabolic CNS effects that preserve muscle during caloric deficit. Amylin co-agonism also allows weight loss at lower semaglutide doses, potentially reducing catabolic stimulus.
Verdict: CagriSema is the most accessible plausibly muscle-sparing GLP-1 combination if approved. It is not proven to preserve muscle — only numerically better than semaglutide monotherapy in Phase 3 substudies.
The Critical Evidence Gap: Physical Function
Evidence grade: Gap
Zero of the 36 RCTs in the Annals systematic review measured physical function as a primary endpoint — no grip strength, no SPPB, no falls. This is the most critical gap in the field.
Implications:
- The 34.9% FFM figure cannot be labeled clinically significant without functional outcome data
- Whether FFM loss translates to increased falls, fractures, or mobility impairment is unknown
- The semaglutide BMD reduction signal (lumbar spine modest reduction; no fracture rate increase demonstrated) is a monitoring flag, not a proven harm signal
High-risk populations with no data:
- Elderly (>65) — excluded from most GLP-1 obesity RCTs
- Sarcopenic or frail patients — excluded
- Post-bariatric surgery — unstudied
DXA and Wearable Monitoring Guidance
Primary tool: DXA
DXA is the gold standard for tracking FFM changes during GLP-1 therapy. DXA was used in all pivotal body composition substudies.
| Timepoint | Action |
|---|---|
| Baseline (week 0–1) | DXA before or during first week of therapy |
| 6 months | DXA to assess body composition trajectory |
| 12 months | DXA for comprehensive assessment |
Consumer BIA smart scales are not accurate enough to detect the 2–5 kg FFM changes typical of GLP-1 therapy in the short term (±3–5 kg error). Use for directional trends over 3–6 months only, measured consistently (same time, same hydration conditions).
Functional proxy: Grip strength every 3 months
- Validated, cheap, field-ready proxy for overall muscle strength
- No GLP-1-specific data exists, but it is the best functional proxy available
- Decline >10–15% from personal baseline warrants clinical evaluation
Activity proxy: Step count monitoring
- GLP-1 reduces NEAT and spontaneous activity
- Monitor for sustained step count decline >20% from baseline — an early warning sign for activity-driven muscle loss
RMR and serum creatinine: not recommended as primary FFM monitoring tools — both are confounded by GLP-1-induced metabolic adaptation and hydration changes.
See GLP-1 Body Composition for the full detection model and alarm thresholds.
Evidence Summary
| Claim | Grade | Source |
|---|---|---|
| Median 34.9% of GLP-1 weight loss is FFM; 68% of 36 RCTs exceed 25% benchmark | Supported | ACP 2026 / PMID 39481534 |
| Bimagrumab + semaglutide preserves/increases lean mass (Phase 2 RCT) | Confirmed | PMID 41772149 |
| Bimagrumab monotherapy gains lean mass in humans | Confirmed | PMID 41772149 |
| CagriSema numerically better FFM preservation vs semaglutide alone | Supported | PMID 40544433 |
| Semaglutide modestly reduces lumbar spine BMD (no fracture rate increase) | Reported | STEP 1 substudy |
| Zero RCTs measured physical function as primary endpoint | Gap | PMID 39481534 |
| Resistance training + protein prevents GLP-1 FFM loss | Gap | No registered trial exists |
| MariTide muscle effect unknown | Gap | PMID 40549887 |
| FFM loss comparable to bariatric surgery (25–30%) | Supported | PMID 39481534 |
What Not to Claim
- Do NOT claim tirzepatide “spares muscle” compared to semaglutide — no head-to-head DXA RCT
- Do NOT claim the 34.9% FFM loss is “clinically significant” — zero functional outcome data
- Do NOT claim MariTide spares or worsens muscle — no data
- Do NOT claim CagriSema “preserves muscle” — only numerically better than semaglutide; not a primary endpoint
Related Notes
- GLP-1 Muscle Preservation — parent hub; broader lean mass evidence
- GLP-1 Body Composition — detection model; DXA/BIA/grip strength alarm thresholds
- Bimagrumab Semaglutide Combo Obesity — full BELIEVE trial detail
- Protein Intake GLP-1 Glucagon — protein protocol for GLP-1 users
- GLP-1 Nutritional Protocol — nutritional guidance during GLP-1 therapy
- mTOR AMPK Muscle Catabolism — central signaling during caloric deficit
- ActRII Myostatin Pathway — bimagrumab mechanism
Supplement note — Batch 67 / April 2026 — GLP-1 FFM Systematic Review ACP 2026 Core PMIDs: PMID 39481534 | PMID 41772149 | PMID 40544433